AEON icon

AEON Biopharma
AEON

Overview Fund Trends Analyst Outlook Journalist POV

21 hedge funds and large institutions have $20.5M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less capital invested

Capital invested by funds: $ → $

93% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 69

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
21
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$1.32M
2
+$549K
3
+$162K
4
CCM
CAAS Capital Management
New York
+$120K
5
FTUS
Flow Traders U.S.
New York
+$108K

Top Sellers

1
-$13.3M
2
-$12.8M
3
-$12.6M
4
ECP
Empyrean Capital Partners
California
-$12.2M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$11.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
51
–
52
–
53
–
54
–
55
–
56
–
57
–
58
–
59
–
60
–
61
–
62
–
63
–
64
–
65
–
66
–
67
–
68
–
69
–
70
–
71
–
72
–
73
–
74
–
75
–
1 2
3
4